ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria

This study has been completed.
Study NCT00002268.   Last updated on June 23, 2005.   Information provided by NIH AIDS Clinical Trials Information Service

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:
1 Conditions listed in this trial
Cytomegalovirus Infections
HIV Infections
2 Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
Immunologic Deficiency Syndromes
Infection
3 More general conditions related to this trial
DNA Virus Infections
Herpesviridae Infections
Immune System Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
4 Interventions listed in this trial
Sevirumab
5 Additional drug interventions recognized in this trial
Antibodies, Monoclonal
6 More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
7 Sponsors listed in this trial
Sandoz Inc.




Links to all studies - primarily for crawlers